川宁生物(301301)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301301 川宁生物

已收盘 03-05 15:00:00

{"stockData":{"symbol":"301301","market":"SZ","secType":"STK","nameCN":"川宁生物","latestPrice":10.57,"timestamp":1772694207000,"preClose":10.93,"halted":0,"volume":21453600,"delay":0,"changeRate":-0.0329,"floatShares":618000000,"shares":2230000000,"eps":0.4197,"marketStatus":"已收盘","change":-0.36,"latestTime":"03-05 15:00:00","open":10.97,"high":11.02,"low":10.51,"amount":231000000,"amplitude":0.0467,"askPrice":10.58,"askSize":362,"bidPrice":10.57,"bidSize":88,"shortable":0,"etf":0,"ttmEps":0.4197,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":5,"adr":0,"adjPreClose":10.93,"symbolType":"stock","openAndCloseTimeList":[[1772674200000,1772681400000],[1772686800000,1772694000000]],"highLimit":12.02,"lowLimit":9.84,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2230085000,"isCdr":false,"pbRate":3.08,"roa":"--","peRate":25.184656,"roe":"7.63%","epsLYR":0.63,"committee":0.180567,"marketValue":23572000000,"turnoverRate":0.0347,"status":1,"floatMarketCap":6530000000},"requestUrl":"/m/hq/s/301301","defaultTab":"news","newsList":[{"id":"2617842511","title":"川宁生物：公司产品境外销售地主要为印度、香港等地区","url":"https://stock-news.laohu8.com/highlight/detail?id=2617842511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617842511?lang=zh_cn&edition=full","pubTime":"2026-03-05 15:45","pubTimestamp":1772696717,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物(301301)03月05日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司抗生素药物主要出口印度吗？谢谢川宁生物回复：尊敬的投资者，您好。公司产品境外销售地主要为印度、香港等地区。谢谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500020812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301301","MNDmain","BK0239"],"gpt_icon":0},{"id":"2617511875","title":"川宁生物：甲醇蛋白项目是公司重点推进的核心项目之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2617511875","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617511875?lang=zh_cn&edition=full","pubTime":"2026-03-05 15:45","pubTimestamp":1772696717,"startTime":"0","endTime":"0","summary":"甲醇蛋白项目是公司重点推进的核心项目之一，目前该项目已根据下游客户反馈正在进行相关改进型实验。甲醇蛋白具有广阔的工业化生产前景，甲醇蛋白是以甲醇为碳源，通过培养微生物生产的单细胞蛋白，具有成本低、质量稳定可控等优点，也被认为是食用和饲用蛋白的有效替代品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500020814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301301","BK0239"],"gpt_icon":0},{"id":"2601486414","title":"川宁生物涨5.51%，民生证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601486414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601486414?lang=zh_cn&edition=full","pubTime":"2026-01-06 15:43","pubTimestamp":1767685383,"startTime":"0","endTime":"0","summary":"今日川宁生物（301301）涨5.51%，收盘报10.92元。2025年10月28日，民生证券研究员王维肖,杨涛发布了对川宁生物的研报《2025年三季报点评：抗生素淡季业绩承压筑底，合成生物产能稳步爬坡》，该研报对川宁生物给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为79.81%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信建投的王云鹏。川宁生物（301301）个股概况：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600020560.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301301","161027"],"gpt_icon":0},{"id":"2594899322","title":"川宁生物董事会通过2026年度关联交易预计及募投项目调整议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2594899322","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594899322?lang=zh_cn&edition=full","pubTime":"2025-12-25 10:37","pubTimestamp":1766630229,"startTime":"0","endTime":"0","summary":"中访网数据 伊犁川宁生物技术股份有限公司于2025年12月23日召开第二届董事会第十三次会议，审议通过多项重要议案。会议在关联董事回避表决的情况下，通过了《关于预计公司2026年度日常关联交易情况的议案》，该议案尚需提交2026年第一次临时股东会审议，届时关联股东需回避表决。公司独立董事专门会议及保荐机构均对上述议案发表了同意的意见。此外，董事会决定将于2026年1月9日召开2026年第一次临时股东会，审议相关事项。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251225/31891463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["301301","BK0239"],"gpt_icon":0},{"id":"2594289863","title":"川宁生物拟将“上海研究院建设项目”结余资金转投“绿色循环产业园项目”","url":"https://stock-news.laohu8.com/highlight/detail?id=2594289863","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594289863?lang=zh_cn&edition=full","pubTime":"2025-12-25 10:22","pubTimestamp":1766629326,"startTime":"0","endTime":"0","summary":"中访网数据 伊犁川宁生物技术股份有限公司于2025年12月23日召开董事会，审议通过了关于部分募投项目结项并将节余募集资金用于其他募投项目建设的议案。公司决定对已基本建设完毕的“上海研究院建设项目”予以结项，并将该项目产生的节余募集资金用于继续建设“绿色循环产业园项目”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251225/31891449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","301301"],"gpt_icon":0},{"id":"2593140812","title":"川宁生物（301301）披露召开2026年第一次临时股东会通知，12月24日股价上涨0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593140812","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593140812?lang=zh_cn&edition=full","pubTime":"2025-12-24 22:55","pubTimestamp":1766588119,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，川宁生物报收于9.99元，较前一交易日上涨0.2%，最新总市值为222.79亿元。该股当日开盘9.98元，最高10.01元，最低9.92元，成交额达6739.71万元，换手率为1.09%。近日，伊犁川宁生物技术股份有限公司发布公告称，公司将于2026年1月9日召开2026年第一次临时股东会，会议由公司董事会召集，现场会议时间为当日15:00，网络投票时间为同日9:15至15:00。股权登记日为2026年1月5日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400041570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301301"],"gpt_icon":0},{"id":"2591806439","title":"川宁生物（301301）披露控股股东追加承诺自愿延长股份限售期，12月16日股价下跌1.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591806439","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591806439?lang=zh_cn&edition=full","pubTime":"2025-12-16 22:11","pubTimestamp":1765894316,"startTime":"0","endTime":"0","summary":"截至2025年12月16日收盘，川宁生物报收于9.82元，较前一交易日下跌1.01%，最新总市值为218.99亿元。该股当日开盘9.89元，最高9.93元，最低9.78元，成交额达6725.53万元，换手率为1.11%。同日，公司发布公告称，控股股东四川科伦药业股份有限公司及成都科伦宁辉企业管理合伙企业近日出具《关于自愿延长限售股份锁定期的承诺函》。其中，科伦药业持有1,569,887,643股，占总股本70.40%，科伦宁辉持有40,000,000股，占总股本1.79%。原限售截止日为2025年12月27日，现延长至2026年12月27日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600040590.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301301"],"gpt_icon":0},{"id":"2590925325","title":"川宁生物：公司产品用于合成抗菌类药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2590925325","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590925325?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:21","pubTimestamp":1765448475,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物(301301)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：流感病毒严重蔓延,公司的抗生素对其有辅助治疗的作用吗？川宁生物回复：尊敬的投资者，您好！公司作为抗生素中间体生产企业，主要产品包括硫氰酸红霉素、头孢类中间体、青霉素中间体等，上述产品均用于合成抗菌类药物。若流感患者出现细菌性并发症（如细菌性肺炎），临床医生可能根据实际情况使用抗生素类药物进行辅助治疗。公司产品系上述抗生素药物的上游中间体。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100030804.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301301"],"gpt_icon":0},{"id":"2590536592","title":"川宁生物：肌醇已进入生产阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2590536592","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590536592?lang=zh_cn&edition=full","pubTime":"2025-12-11 18:21","pubTimestamp":1765448474,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物12月11日在投资者关系平台上答复投资者关心的问题。肌醇作为公司合成生物学重点产品，已进入生产阶段。公司肌醇已获得饲料添加剂许可证书，广泛应用于水产、禽畜饲料领域。公司将持续推进合成生物学产业化进程，相关进展请关注公司法定披露渠道。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100030803.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301301"],"gpt_icon":0},{"id":"2586478218","title":"川宁生物：合成生物学产品订单较去年同期改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478218","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586478218?lang=zh_cn&edition=full","pubTime":"2025-11-28 20:53","pubTimestamp":1764334386,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物11月28日在投资者关系平台上答复投资者关心的问题。目前合成生物学基地处于产能爬坡阶段，产品包括红没药醇、5-羟基色氨酸、麦角硫因等已逐步进入生产销售阶段。未来公司将通过持续优化生产工艺及拓展市场，推动合成生物业务发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800036417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301301","BK0239"],"gpt_icon":0},{"id":"2586661234","title":"川宁生物：麦角硫因原料已上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2586661234","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586661234?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:21","pubTimestamp":1764145271,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物11月26日在投资者关系平台上答复投资者关心的问题。公司生产的麦角硫因原料已上市，目前主要应用于化妆品原料、保健品原料等领域，并正在积极拓展市场。关于麦角硫因在国内新食品原料的审批进展，目前正处在受理阶段。在产能规划方面，公司原规划麦角硫因年产能为0.5吨，后续将根据市场需求动态调整产能。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600020553.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301301"],"gpt_icon":0},{"id":"2586478090","title":"川宁生物：股东减持属正常市场现象","url":"https://stock-news.laohu8.com/highlight/detail?id=2586478090","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586478090?lang=zh_cn&edition=full","pubTime":"2025-11-25 20:48","pubTimestamp":1764074889,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物11月24日在投资者关系平台上答复投资者关心的问题。关于您提及的部分原始股东减持情况，公司已关注到相关市场动态。根据信息披露规则，股东减持行为系其基于自身资金规划、投资策略等综合考量后的自主决策，公司尊重股东合法合规的权利行使，股东减持行为属于资本市场正常现象，且不影响公司治理结构与持续经营能力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500036060.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301301"],"gpt_icon":0},{"id":"2585545402","title":"川宁生物：暂未布局电解液添加剂VC相关项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2585545402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585545402?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:27","pubTimestamp":1763972832,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物(301301)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司电解液添加剂VC项目现在是不是停产了？如果没有那产能多少？川宁生物回复：尊敬的投资者，您好！公司主营业务为生物发酵及合成生物学产品的研发与生产，主要产品包括硫氰酸红霉素、头孢类中间体、青霉素类中间体以及红没药醇、五羟基色氨酸、麦角硫因、肌醇等合成生物学产品。公司暂未布局电解液添加剂VC相关项目。公司将继续聚焦现有核心业务领域，感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400017108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301301","BK0239"],"gpt_icon":0},{"id":"2585452809","title":"川宁生物：硫氰酸红霉素价格保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=2585452809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585452809?lang=zh_cn&edition=full","pubTime":"2025-11-24 16:27","pubTimestamp":1763972831,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物(301301)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，请问公司三大主营产品6-APA/硫红/7-ACA最新的市场价格分别是多少。川宁生物回复：尊敬的投资者，您好！关于公司主营产品市场价格：硫氰酸红霉素价格保持稳定，与2024年同期基本持平，主要因供需结构稳定；6-APA及青霉素工业盐价格处于近五年历史底部区间波动；头孢类中间体价格年初至今呈小幅波动。感谢您对公司的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400017103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301301","BK0239"],"gpt_icon":0},{"id":"2582247018","title":"川宁生物：麦角硫因原料已上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2582247018","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582247018?lang=zh_cn&edition=full","pubTime":"2025-11-10 18:09","pubTimestamp":1762769348,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物11月10日在投资者关系平台上答复投资者关心的问题。公司生产的麦角硫因原料已上市，目前主要应用于化妆品原料、保健品原料等领域，并正在积极拓展市场 。根据公开信息，麦角硫因在化妆品领域作为高效抗氧化剂，已用于高端产品配方；在食品保健品领域，可用于改善口感、延长保质期及制成胶囊等剂型 。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000024545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301301","BK0239"],"gpt_icon":0},{"id":"2582824084","title":"川宁生物：合成生物学量产产品有红没药醇、五羟基色氨酸等","url":"https://stock-news.laohu8.com/highlight/detail?id=2582824084","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582824084?lang=zh_cn&edition=full","pubTime":"2025-11-10 18:09","pubTimestamp":1762769347,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物11月10日在投资者关系平台上答复投资者关心的问题。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000024543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301301"],"gpt_icon":0},{"id":"2578622927","title":"图解川宁生物三季报：第三季度单季净利润同比下降49.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578622927","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578622927?lang=zh_cn&edition=full","pubTime":"2025-10-28 02:31","pubTimestamp":1761589873,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物2025年三季报显示，公司主营收入34.36亿元，同比下降22.9%；归母净利润6.11亿元，同比下降43.17%；扣非净利润6.08亿元，同比下降43.44%；其中2025年第三季度，公司单季度主营收入10.87亿元，同比下降13.76%；单季度归母净利润1.57亿元，同比下降49.44%；单季度扣非净利润1.52亿元，同比下降51.01%；负债率23.03%，投资收益-202.52万元，财务费用2540.39万元，毛利率32.8%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102800002073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301301"],"gpt_icon":0},{"id":"2574610929","title":"川宁生物新注册《科伦药业订单管理系统V1.3》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2574610929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574610929?lang=zh_cn&edition=full","pubTime":"2025-10-11 02:00","pubTimestamp":1760119248,"startTime":"0","endTime":"0","summary":"证券之星消息，近日川宁生物（301301）新注册了《科伦药业订单管理系统V1.3》项目的软件著作权。今年以来川宁生物新注册软件著作权2个，较去年同期增加了100%。结合公司2025年中报财务数据，今年上半年公司在研发方面投入了6763.37万元，同比增135%。通过天眼查大数据分析，伊犁川宁生物技术股份有限公司共对外投资了14家企业，参与招投标项目42次；财产线索方面有商标信息9条，专利信息154条，著作权信息2条；此外企业还拥有行政许可41个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101100000920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1934453819.USD","002422","LU1064131003.USD","LU1979443071.USD","LU2148510915.USD","LU1064130708.USD","301301","BK0060","BK0239"],"gpt_icon":0},{"id":"2569273193","title":"股市必读：川宁生物（301301）9月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2569273193","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569273193?lang=zh_cn&edition=full","pubTime":"2025-09-23 00:59","pubTimestamp":1758560354,"startTime":"0","endTime":"0","summary":"截至2025年9月22日收盘，川宁生物报收于11.3元，下跌0.79%，换手率1.85%，成交量11.41万手，成交额1.3亿元。董秘最新回复投资者： 请问公司现阶段生物制剂生产的主要原料是什么？当日关注点来自交易信息汇总：9月22日主力资金净流出2511.53万元，显示主力短期内可能持谨慎态度。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092300001058.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301301"],"gpt_icon":0},{"id":"2569175204","title":"川宁生物：公司目前的维生素类产品有肌醇","url":"https://stock-news.laohu8.com/highlight/detail?id=2569175204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569175204?lang=zh_cn&edition=full","pubTime":"2025-09-22 16:03","pubTimestamp":1758528199,"startTime":"0","endTime":"0","summary":"证券之星消息，川宁生物(301301)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问公司有哪些维生素类产品？川宁生物回复：尊敬的投资者，您好，公司目前的维生素类产品有肌醇，后续还会有一些维生素类、氨基酸类等合成生物学产品推出，感谢你对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092200018764.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301301"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772732410508,"stockEarnings":[{"period":"1week","weight":-0.0588},{"period":"1month","weight":-0.0303},{"period":"3month","weight":0.0222},{"period":"6month","weight":-0.0927},{"period":"1year","weight":-0.1828},{"period":"ytd","weight":0.0424}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"伊犁川宁生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"51300人(较上一季度减少5.44%)","perCapita":"12042股","listingDate":"2022-12-27","address":"新疆维吾尔自治区伊犁哈萨克自治州霍尔果斯市霍尔果斯经济开发区伊宁园区拱宸路1号","registeredCapital":"223008万元","survey":"　　伊犁川宁生物技术股份有限公司的主营业务是生物发酵技术的研发和产业化。公司的主要产品是硫氰酸红霉素、6-APA、青霉素G钾盐、7-ACA、7-ADCA、D-7ACA。","listedPrice":5},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"川宁生物(301301)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供川宁生物(301301)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"川宁生物,301301,川宁生物股票,川宁生物股票老虎,川宁生物股票老虎国际,川宁生物行情,川宁生物股票行情,川宁生物股价,川宁生物股市,川宁生物股票价格,川宁生物股票交易,川宁生物股票购买,川宁生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"川宁生物(301301)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供川宁生物(301301)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}